Confirmed best overall responses
| Continuous dosing cohort (n=30) | Intermittent dosing cohort (n=10) | All patients (n=40) | |
| Objective response* | 13 (43.3; 25.5–62.6) | 0 (0; 0–30.8) | 13 (32.5; 18.6–49.1) |
| Disease control† | 19 (63.3; 43.9–80.1) | 4 (40.0; 12.2–73.8) | 23 (57.5; 40.9–73.0) |
| Clinical benefit‡ | 10 (33.3; 17.3–52.8) | 1 (10.0; 0.3–44.5) | 11 (27.5; 14.6–43.9) |
| Best overall response | |||
| Complete response | 0 | 0 | 0 |
| Partial response | 13 (43.3) | 0 | 13 (32.5) |
| Stable disease | 6 (20.0) | 4 (40.0) | 10 (25.0) |
| Progressive disease | 9 (30.0) | 5 (50.0) | 14 (35.0) |
| Not evaluable§ | 2 (6.7) | 1 (10.0) | 3 (7.5) |
Data are n (%; 95% CI) or n (%).
*Objective responses were confirmed by repeat imaging 4 weeks later.
†Includes patients who achieved an objective response or had stable disease as their best response.
‡Includes patients who achieved an objective response or had stable disease as their best response for 24 weeks or more.
§Signifies patients with unevaluable responses.